US FDA expands approval for Merck’s PREVYMIS (letermovir)
Pharmaceutical Technology
JUNE 7, 2023
The US Food and Drug Administration (FDA) has granted approval for a new indication for Merck’s PREVYMIS (letermovir) to prevent cytomegalovirus (CMV) disease in high-risk adult kidney transplant recipients. The latest move follows a priority review of a supplemental new drug application (sNDA) for the therapy.
Let's personalize your content